An Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose of MMV390048 in Adult Patients With Acute, Uncomplicated Plasmodium Vivax or Falciparum Malaria Monoinfection Over a 35 Day Period
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2017
At a glance
- Drugs MMV 390048 (Primary)
- Indications Malaria
- Focus Proof of concept; Therapeutic Use
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
- 19 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.